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ypertrophic Cardiomyopathy
here Is Much More to the
ecipe Than Just Outflow Obstruction*
teve R. Ommen, MD, FACC
ochester, Minnesota
or decades, cardiologists have maintained a keen fascina-
ion with hypertrophic cardiomyopathy (HCM), resulting
n a robust body of literature. By and large the pathophys-
ologic mechanisms, consequences, and treatment of left
entricular outflow tract obstruction have garnered a large
roportion of the published reports. In fact, population-
ased studies shed light on the fact that the nonobstructive
ariants of HCM are more common than the obstructive
orms. That sudden cardiac death can be a prominent
eature in some families, that atrial fibrillation manifests
evere clinical disability in subsets of HCM patients, and
hat hundreds of mutations in the genetic code for cardiac
arcomeric proteins have been implicated in the pathogen-
sis of the disease all underscore the marked variability in
he complex entity that is HCM. In this issue of the Journal,
iagini et al. (1) highlight another important facet of
CM: the possibility of progression to an end-stage or
burned out” dilated phase.
See page 1543
Previous investigations and anecdotal reports have sug-
ested that late wall thinning and chamber dilation will
evelop in approximately 5% of patients with HCM. The
ew data reported in this issue confirm this prevalence, but
lso introduce the incident rate of new cases of this dilated
hase (0.5% per year). These data suggest that those in
hom hypertrophy manifests at a younger age, those with
he greatest amount of hypertrophy, and those with a
ignificant family history of HCM are more likely to have
all thinning and left ventricular cavity dilatation in the
ong term. Although the number of patients in this study is
mall (reflecting the rarity of dilated-phase HCM) and does
ot allow clear prospective identification of those at in-
reased risk for dilation, these findings need to be consid-
red in the context of the genetic and metabolic recipe
f HCM.
Beginning with the sentinel descriptions of mutations in
he genetic codes for cardiac sarcomeric proteins, investiga-
ors have sought to uncover the molecular pathogenesis by
hich these mutations actually produce left ventricular
*Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theg
merican College of Cardiology.
From the Mayo Clinic College of Medicine, Rochester, Minnesota.ypertrophy. Abnormal sarcomere structure, calcium han-
ling, and decreased or increased sarcomeric unit function
ave all been implicated in the development of the inap-
ropriate myocyte disarray, fibrosis, and hypertrophy that
ypify HCM (2,3). There remains a lack of consensus on a
nifying pathogenetic model for either the initial develop-
ent of hypertrophy or the rare occurrence of late regression
f hypertrophy.
Myocardial fibrosis is common in the histologic exami-
ation of the hearts of patients with HCM. Those patients
ith late wall thinning show a gross overrepresentation of
his fibrosis, leading to the reasonable hypothesis that
yocardial ischemia may play a role in the process (4). An
ncreased myocardial oxygen demand caused by the hyper-
rophy and abnormal loading conditions, coupled with
bnormal capillary density, would favor ischemia as an
mportant factor in HCM. Numerous studies have shown
bnormal perfusion and decreased coronary flow reserve in
he hearts of patients with HCM (5,6). The magnitude of
he decrement in flow reserve has also been correlated with
ncreasing systolic dysfunction (7). The implication is that
ither the heart that is undergoing transition to dilatation is
ipping into its flow reserve, or the microvascular impair-
ent actually causes the fibrosis and dilatation. In either
cenario, these hearts seem to be in or on the brink of crisis.
The tenuous biochemical environment in HCM is fur-
hered by evidence of down-regulated beta-adrenergic re-
eptors, heightened sympathetic activity, and increased
ardiac catecholamine levels (8,9). The potential deleterious
ffects of a prolonged hyperadrenergic state can be drawn
rom patients with primary idiopathic dilated cardiomyop-
thy (DCM). It seems plausible that an environment
avoring ischemia and with elevated sympathetic neuro-
ransmitter levels could lead to fibrotic transition. Certainly
here also are other commonalities between HCM and
CM. Mutations in some of the same sarcomeric proteins
an cause either type of cardiomyopathy. In fact, there are
emarkable similarities in vast gene expression arrays and
nergy use between patients with DCM and late-stage
ilatation HCM (10–13).
The study by Biagini et al. (1), with the suggestion that
atients with clear hypertrophy at a young age with a greater
agnitude of hypertrophy, seems to support the concept
hat energetic crisis and ultimate energetic failure may lead
o late-stage transformation. Perhaps these patients with
arly and more complete disease expression represent those
hat reach the energetic brink more readily. Possibly, the
arly expression or rapid progression results in increased
etabolic demands and more inefficiency, which ultimately
eads to cell death and fibrotic replacement. Whether
pecific therapies targeted at delaying the progression of
ypertrophy or at counteracting the effects of cat-
cholamines will have any benefit will be difficult to show
iven the rarity of dilated-phase HCM.
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Editorial Comment October 18, 2005:1551–2In the making of fine wines, the basic ingredients are the
ame, but it is the environment, the handling, the timing,
nd the exposure to other impurities that ultimately results
n the enjoyment (or not) of the final product. Perhaps the
ommonly proclaimed heterogeneity in the expression of
CM is the result of a “vinification” of the cardiac myocyte
uch that sarcomeric mutations, modifier gene polymorphisms
14), local loading conditions, and as-yet-undetermined
actors all combine in the right sequences and concentra-
ions to produce each variety of clinical HCM. Cardiolo-
ists need to continue to try to understand this very complex
ondition.
eprint requests and correspondence: Dr. Steve R. Ommen,
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